Clinical Trial

A new oral tablet from Entera Bio could replace painful daily injections for millions with severe osteoporosis, a move validated by a top scientific conference.

Healis Therapeutics gets FDA nod for Tyemvers, a botulinum toxin therapy for depression. Can a drug that paralyzes frown muscles disrupt mental healthcare?

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.

Oblenio Bio's LBL-051 enters human trials, offering hope for a true "immune reset" and drug-free remission for severe autoimmune disease patients.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

A positive safety review for Molecure's novel sarcoidosis drug OATD-01 de-risks its development, offering new hope for patients and boosting the company's strategic value.

Exicure is settling a $1M debt with stock, a move to preserve its dwindling cash. Can this gamble save its new focus on blood cancer therapy or just delay the inevitable?

Ceruvia Lifesciences secures $8M for a non-hallucinogenic LSD analog to treat cluster headaches, offering a potential breakthrough for a severe pain disorder.

The first Animal Longevity Summit marks a pivotal moment, as research into pet aging and biotech investment converge to create a new frontier in healthspan.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

A novel postbiotic protein matches whey's muscle-building power in a landmark study, signaling a major disruption for the sports nutrition and food industries.

Regeneron's Q2 results reveal soaring sales from Dupixent and EYLEA HD, a pivotal pipeline, and a major financial reset with Sanofi. What's next?

Basking Biosciences' BB-031 targets a key clotting protein, dissolving clots hours later than current drugs. With a unique reversal agent, it could transform stroke care.

Lōkahi Therapeutics aims to turn 15 injections into one for its pain drug LT-100, a move that could transform patient care and unlock major commercial value.

Latigo Biotherapeutics' new drug LTG-001 shows superior, faster pain relief than Vicodin in a major trial, offering a potent new tool against the opioid crisis.

The FNIH is launching a landmark study using AI and biomarkers to redefine depression, moving beyond guesswork toward precision care for millions.

A new study suggests A2-protein infant formula may boost growth, a potential game-changer. But with preliminary data, experts urge caution.

Lantern Pharma's EMA-cleared trial for LP-184 uses a dual-biomarker strategy, targeting a multi-billion dollar market where patient options are scarce.

Dasher Neuroscience completes Phase 2 enrollment for its AI-designed drug for MSA, a fatal disease with no cure, signaling a major step toward a first-in-class therapy.

An Australian biotech's breakthrough study on fucoidan, a seaweed compound, offers a safe, clinically-proven new option for men suffering from BPH.